Onco Therapy Science, Inc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Onco Therapy Science, Inc with three other
companies in this sector in Japan:
3-D Matrix Ltd
sales of 328.85 million Japanese Yen [US$3.02 million]
of which 100%
was Medical Products),
DNA Chip Research, Inc.
(360.81 million Japanese Yen [US$3.31 million]
BrightPath Biotherapeutics Co Ltd
(155.81 million Japanese Yen [US$1.43 million]
During the year ended March of 2019, sales at
Onco Therapy Science, Inc were ¥280.59 million (US$2.57 million).
increase of 32.8%
versus 2018, when the company's sales were ¥211.25 million.
Despite this increase, sales are still
below the level achieved in 2017, when Onco Therapy Science, Inc
reported sales of ¥286.67 million.
Sales of Cancer Precision Business saw an increase
that was more than double the company's growth rate: sales were up
1,229.5% in 2019, from
¥5.68 million to ¥75.55 million.
Not all segments of Onco Therapy Science, Inc experienced an increase in sales in 2019:
sales of Research and Development of Pharmaceutic fell 0.3% to ¥205.03 million.